Tirzepatide vs Retatrutide: A Canadian Research Comparison (2026)

Reviewed September 6, 2026. Tirzepatide targets GIP and GLP-1 receptors; retatrutide adds glucagon-receptor activity. Both have clinical research records, but their regulatory status and the maturity of the evidence differ. A larger weight-change percentage from a separate study does not establish that one is superior.

This comparison explains the research distinctions and Canadian status. It does not compare approved prescription medicines with research vials as interchangeable products.

Tirzepatide vs retatrutide: the main differences

Health Canada drug-status context · Retatrutide developer status · TRIUMPH-5 registry.

What the additional glucagon receptor means

Retatrutide’s triple activity makes it a distinct molecule, not simply another concentration of tirzepatide. The discovery research describes its receptor pharmacology and early metabolic findings. Receptor counts alone cannot predict every clinical outcome, tolerability difference or experimental result. Original retatrutide discovery paper.

For laboratory comparisons, molecule identity, documented material form and analytical quality must be established before interpreting a difference between samples. A catalogue name or nominal vial amount does not establish those properties.

What the weight-loss studies actually show

In SURMOUNT-1, 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, were randomized to tirzepatide or placebo. At 72 weeks, the 15 mg study arm showed mean weight change of −20.9%, versus −3.1% with placebo. Gastrointestinal events were common. Jastreboff et al., NEJM (2022).

Retatrutide’s Phase 2 obesity trial followed a different population for 48 weeks. Its often-quoted 24.2% result came from the 12 mg study arm. Retatrutide Phase 2 publication. The studies differ in size, follow-up and design; subtracting the two percentages does not estimate a head-to-head treatment advantage.

The June 2026 Lancet publication adds Phase 3 evidence in type 2 diabetes. TRANSCEND-T2D-1 paper. TRIUMPH-1, -2 and -3 announcements address other populations and time points. Read the retatrutide research timeline for the individual results, analysis methods and publication status.

Has retatrutide been compared directly with tirzepatide?

Yes, a direct comparison is underway in TRIUMPH-5. As of the registry check for this review, no results were posted and primary completion was estimated for November 2026. The correct distinction is between an ongoing comparative trial and a completed published result. TRIUMPH-5 study record.

Until results are available, this page does not label either compound the clinical winner. Future evidence should be assessed using the trial’s prespecified endpoints, uncertainty estimates and adverse events, not only its largest reported weight change.

Safety findings are part of the comparison

Both programs report gastrointestinal adverse events. Tolerability, discontinuation, serious events and the populations excluded from a trial all affect interpretation. Separate trials may use different collection methods and follow-up, so their adverse-event percentages are not a controlled comparison either.

Online experiences cannot establish causality or the identity of a purchased product. A report of a benefit or side effect should not be treated as equivalent to a randomized trial with documented material, eligibility criteria and follow-up.

Are tirzepatide and retatrutide approved in Canada?

Health Canada identifies Mounjaro and Zepbound as authorized prescription products containing tirzepatide. Retatrutide remains investigational according to its developer. The existence of an approved tirzepatide medicine does not authorize every product sold under the ingredient name. Health Canada’s product-status explanation · Retatrutide status.

A Canadian research listing should therefore distinguish laboratory material from authorized treatment. Neither a research-use label nor a purity percentage establishes clinical equivalence, sterility or suitability for human use.

Comparing research-vial documentation

For listed amounts, current pricing and availability, consult the retatrutide research vials and tirzepatide research product pages. Different milligram amounts across different molecules are not equivalent measures of pharmacological activity.

Request a COA for the exact lot. Match the product name and batch identifier, then read the test date, laboratory and methods. Chromatographic purity does not establish measured vial content; identity testing does not establish sterility. Look for the result relevant to the property being assessed.

Related research reading

The retatrutide clinical trials guide separates full journal papers from sponsor reports. The semaglutide vs tirzepatide vs retatrutide guide provides broader context for single, dual and triple receptor activity. The research centre collects the site’s evidence guides.

Review scope: original clinical publications, current developer disclosures, the trial registry and Health Canada’s published explanation, checked September 6, 2026. Research products are supplied for laboratory research only, not for human or veterinary use.